Lujun Shen1,2, Qifeng Chen1,2, Changsheng Yang2,3, Ying Wu1,2, Hui Yuan1,2, Shuanggang Chen1,2, Shunling Ou1,2, Yiquan Jiang1,2, Tao Huang1,2, Liangru Ke4, Jinqing Mo5, Ziqing Feng5, Penghui Zhou2, Weijun Fan1,2. 1. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, China. 3. Department of Spine Surgery, Third Affiliated Hospital of Southern Medical University, Guangzhou, China. 4. Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. 5. Zhong Shan Medical School, Sun Yat-sen University, M, China.
Abstract
Background: PR domain zinc finger protein 1 (PRDM1) is a regulator of both B cell and T cell differentiation and plays a critical role in immunosuppression. Its role in tumor immunity and correlation with drug response remain unknown. Methods: This work comprehensively analyzed the transcriptional expression pattern of the PRDM1 among 33 types of malignancies from The Cancer Genome Atlas and the Genotype-Tissue Expression projects. Besides, correlation of the PRDM1 with cancer prognosis, immune infiltrates, checkpoint markers, cancer stemness and drug response were explored. Results: High expression level of PRDM1 were observed in ACC, COAD, LAML, LGG, LUAD, OV, PAAD, STAD, TGCT. Cox regression model showed high expression of PRDM1 in tumor samples correlates with poor prognosis in LGG, PAAD, UVM while favorable prognosis in KIRC, SKCM and THCA. PRDM1 expression positively correlates with the expression of LAG3, CTLA4, PDCD1 (PD-1), CD274 (PD-L1), PDCD1LG2 (PD-L2), TIGIT in the majority of 33 cancer types. PRDM1 positively correlated with TNFRSF14 in LGG and UVM among cancers with unfavorable prognosis; this correlation were weak or even negative in cancers with favorable prognosis. The top negatively enriched KEGG terms in high PRDM1 subgroup were B cell receptor signaling, T cell receptor signaling, and the top negatively enriched HALLMARK terms included IL-2-STAT5 signaling and allograft rejection. The expression of PRDM1 was found positively correlated with cancer stemness in CHOL, KIRP, TGCT, THYM and UVM. A series of targeted drugs and small-molecule drugs with promising efficacy predicted by PRDM1 level were identified. Conclusion: The clinical significance and biological impact of high transcriptional expression of PRDM1 differs across different cancers. Inhibiting the PRDM1-dependent signaling could be a novel and promising strategy of immunotherapy in cancers including LGG, PAAD and UVM.
Background: PR domain zinc finger protein 1 (PRDM1) is a regulator of both B cell and T cell differentiation and plays a critical role in immunosuppression. Its role in tumor immunity and correlation with drug response remain unknown. Methods: This work comprehensively analyzed the transcriptional expression pattern of the PRDM1 among 33 types of malignancies from The Cancer Genome Atlas and the Genotype-Tissue Expression projects. Besides, correlation of the PRDM1 with cancer prognosis, immune infiltrates, checkpoint markers, cancer stemness and drug response were explored. Results: High expression level of PRDM1 were observed in ACC, COAD, LAML, LGG, LUAD, OV, PAAD, STAD, TGCT. Cox regression model showed high expression of PRDM1 in tumor samples correlates with poor prognosis in LGG, PAAD, UVM while favorable prognosis in KIRC, SKCM and THCA. PRDM1 expression positively correlates with the expression of LAG3, CTLA4, PDCD1 (PD-1), CD274 (PD-L1), PDCD1LG2 (PD-L2), TIGIT in the majority of 33 cancer types. PRDM1 positively correlated with TNFRSF14 in LGG and UVM among cancers with unfavorable prognosis; this correlation were weak or even negative in cancers with favorable prognosis. The top negatively enriched KEGG terms in high PRDM1 subgroup were B cell receptor signaling, T cell receptor signaling, and the top negatively enriched HALLMARK terms included IL-2-STAT5 signaling and allograft rejection. The expression of PRDM1 was found positively correlated with cancer stemness in CHOL, KIRP, TGCT, THYM and UVM. A series of targeted drugs and small-molecule drugs with promising efficacy predicted by PRDM1 level were identified. Conclusion: The clinical significance and biological impact of high transcriptional expression of PRDM1 differs across different cancers. Inhibiting the PRDM1-dependent signaling could be a novel and promising strategy of immunotherapy in cancers including LGG, PAAD and UVM.
Authors: Karuna Ganesh; Zsofia K Stadler; Andrea Cercek; Robin B Mendelsohn; Jinru Shia; Neil H Segal; Luis A Diaz Journal: Nat Rev Gastroenterol Hepatol Date: 2019-06 Impact factor: 46.802
Authors: Na Li; Xiude Fan; Xiaoyun Wang; Huan Deng; Kun Zhang; Xiaoge Zhang; Ye Wang; Qunying Han; Yi Lv; Zhengwen Liu Journal: Int Immunopharmacol Date: 2019-05-14 Impact factor: 4.932
Authors: Taiwen Li; Jingyu Fan; Binbin Wang; Nicole Traugh; Qianming Chen; Jun S Liu; Bo Li; X Shirley Liu Journal: Cancer Res Date: 2017-11-01 Impact factor: 12.701
Authors: Norio Chihara; Asaf Madi; Takaaki Kondo; Huiyuan Zhang; Nandini Acharya; Meromit Singer; Jackson Nyman; Nemanja D Marjanovic; Monika S Kowalczyk; Chao Wang; Sema Kurtulus; Travis Law; Yasaman Etminan; James Nevin; Christopher D Buckley; Patrick R Burkett; Jason D Buenrostro; Orit Rozenblatt-Rosen; Ana C Anderson; Aviv Regev; Vijay K Kuchroo Journal: Nature Date: 2018-06-13 Impact factor: 49.962
Authors: Mayumi Saito; Aarthi Rajesh; Carrie Innes; Rachael van der Griend; Peter Fitzgerald; Bryony Simcock; Peter Sykes; Merilyn Hibma Journal: J Cancer Res Clin Oncol Date: 2022-04-06 Impact factor: 4.322